{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:44:46Z","timestamp":1792154686707,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jchf.2026.103295","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:26:28Z","timestamp":1785875188000},"page":"103295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["National Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5728-7848","authenticated-orcid":false,"given":"Mohammad","family":"Keykhaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla Y.","family":"Hsue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-3649","authenticated-orcid":false,"given":"Boback","family":"Ziaeian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Kittleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MaryAnn","family":"Villarreal-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Hallaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0666-8461","authenticated-orcid":false,"given":"Mattheus","family":"Ramsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyoo A.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-8093","authenticated-orcid":false,"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2026.103295_bib1","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1161\/CIR.0000000000001412","article-title":"2026 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"153","author":"Palaniappan","year":"2026","journal-title":"Circulation"},{"issue":"2026","key":"10.1016\/j.jchf.2026.103295_bib2","first-page":"439","article-title":"heart failure epidemiology and outcomes statistics an updated 2025 report from the Heart Failure Society of America","volume":"32","author":"Writing Committee Members. HF STATS","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103295_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2026.103295_bib4","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2026.103295_bib5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2026.103295_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2026.103295_bib7","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2026.103295_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2026.103295_bib9","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2026.103295_bib10","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2026.103295_bib11","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jchf.2024.03.001","article-title":"Eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed heart failure","volume":"12","author":"Greene","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103295_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2026.02.047","article-title":"Guideline-directed medical therapy trends in the United States: an analysis of three million individuals","author":"Villarreal-Gonzalez","year":"2026","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103295_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103295_bib14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jchf.2019.12.015","article-title":"Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF","volume":"8","author":"Vaduganathan","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103295_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamacardio.2023.0241","article-title":"Quality of care and outcomes among patients hospitalized for heart failure in rural vs urban US hospitals: the get with the guidelines-heart failure registry","volume":"8","author":"Pierce","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2026.103295_bib16","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/jamacardio.2021.3651","article-title":"Potential implications of expanded US Food and Drug Administration labeling for sacubitril\/valsartan in the US","volume":"6","author":"Vaduganathan","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2026.103295_bib17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamacardio.2021.0372","article-title":"Comparison of New York Heart Association class and patient-reported outcomes for heart failure with reduced ejection fraction","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2026.103295_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ejhf.2864","article-title":"Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failure","volume":"25","author":"Talha","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.103295_bib19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jacc.2020.12.026","article-title":"Patients hospitalized for de novo versus worsening chronic heart failure in the United States","volume":"77","author":"Greene","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"suppl 1","key":"10.1016\/j.jchf.2026.103295_bib20","first-page":"S40","article-title":"Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction","volume":"45","author":"Ostrominski","year":"2022","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jchf.2026.103295_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cardfail.2025.11.208","article-title":"Guideline directed medical therapy treatment patterns in heart failure stratified by ejection fraction","volume":"32","author":"Lam","year":"2026","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103295_bib22","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ahj.2011.01.027","article-title":"Potential impact of optimal implementation of evidence-based heart failure therapies on mortality","volume":"161","author":"Fonarow","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2026.103295_bib23","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/jamacardio.2016.1724","article-title":"Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure","volume":"1","author":"Fonarow","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2026.103295_bib24","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jamacardio.2020.0898","article-title":"Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure","volume":"5","author":"Bassi","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2026.103295_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2026.103295_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103295_bib27","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jamacardio.2024.3023","article-title":"Global impact of optimal implementation of guideline-directed medical therapy in heart failure","volume":"9","author":"Tang","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2026.103295_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijcard.2021.01.061","article-title":"Real-world effectiveness and safety of sacubitril\/valsartan in heart failure: a systematic review","volume":"331","author":"Proudfoot","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2026.103295_bib29","first-page":"ehag199","article-title":"Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription","author":"Lindberg","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2026.103295_bib30","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jval.2023.05.011","article-title":"Economic evaluations of guideline-directed medical therapies for heart failure with reduced ejection fraction: a systematic review","volume":"26","author":"Kuan","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.jchf.2026.103295_bib32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jacc.2024.11.011","article-title":"Contributors and solutions to high out-of-pocket costs for heart failure medications: a state-of-the-art review","volume":"85","author":"Lowe","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103295_bib33","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jacc.2023.05.050","article-title":"Bridging treatment implementation gaps in patients with heart failure: JACC Focus Seminar 2\/3","volume":"82","author":"Jalloh","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103295_bib34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2023.03.430","article-title":"Implementing guideline-directed medical therapy for heart failure: JACC Focus Seminar 1\/3","volume":"82","author":"Patolia","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103295_bib35","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/ejhf.3295","article-title":"How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2026.103295_bib36","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jchf.2023.08.015","article-title":"Polypharmacy and the clinical inertia conundrum for GDMT","volume":"11","author":"Page","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103295_bib37","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jchf.2024.08.002","article-title":"Physician-reported reasons for not initiating guideline-directed medical therapy for heart failure","volume":"12","author":"Greene","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103295_bib38","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2026.103295_bib39","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction","volume":"83","author":"Maddox","year":"2024","journal-title":"JACC"},{"key":"10.1016\/j.jchf.2026.103295_bib40","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.35152","article-title":"A natural language processing-based approach for identifying hospitalizations for worsening heart failure within an integrated health care delivery system","volume":"4","author":"Ambrosy","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177926003975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177926003975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:48:17Z","timestamp":1792151297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177926003975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"alternative-id":["S2213177926003975"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2026.103295","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2026.103295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103295"}}